BioSight
Companies
Arcturus Therapeutics Holdings Inc. logo

ARCT

NASDAQSAN DIEGO, CA
Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics develops therapeutic candidates using mRNA technology and lipid-mediated delivery platforms, with a focus on infectious disease and other therapeutic areas. The company's pipeline includes clinical-stage candidates ARCT-810 and ARCT-032, and it has licensed its STARR mRNA technology and LUNAR lipid delivery platform to CSL Seqirus for vaccine development programs including COVID-19 and influenza candidates. Arcturus is advancing multiple research and development programs through preclinical studies and clinical trials while generating revenue through collaboration agreements.

Price history not yet available for ARCT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar